Background: DLEC1 is a tumor-suppressor gene which plays a role in carcinogenesis. The purpose of the current study was to help establish the diagnostic performance of DLEC1 methylation in lung cancer.
Introduction
Lung cancer is a common malignancy from epithelial cells, which has a very high death rate 1 . In China, an estimated 733,300 new cases (509,300 in men and 224,000 in women) of lung cancer could be diagnosed in 2015, and 610,200 deaths (432,400 in men and 177,800 in women)
are estimated to occur from the disease 2 . Despite of the improvement in therapy, 5-year survival of lung cancer remains 18% 3 . Earlier diagnosis of lung cancer may play a significant role in easing the existing burden.
In order to search for more effective diagnostic strategies, molecular approaches have become the research focus to identify molecular biomarkers that can be utilized for early detection 4, 5 . In molecular oncology, inactivation of tumor suppressor genes, overexpression of oncogenes, genetic/epigenetic mutations, and genomic instability are some of the widely investigated mechanisms 6 .
As the bridge between the genetic and environmental aspects, epigenetic modification is proved to play an important role in carcinogenesis 7, 8 . DNA methylation, the most studied epigenetic regulatory mechanism, could behave as a powerful biomarker for early detection of lung cancer 9, 10 . Abnormal methylation of tumor suppressor genes (RARβ, p16, DAPK, RASSF1A, and MGMT) may be advantageous for the early diagnosis of non-small cell lung cancer (NSCLC) 11 13 . In addition, aberrant gene methylation is shown to be associated with smoking, a key risk factor for NSCLC 14 . DLEC1 (deleted in lung and esophageal cancer), located on the 3p22-21.3, is a tumor-suppressor gene which plays a role in the cell-cycle control by inducing G1 arrest 15 . Previous studies showed that DLEC1 promoter methylation was associated with downregulation or loss of DLEC1 expression in lung cancer 16, 17 . Recently, several studies reported that aberrant methylation of DLEC1 had the potential to become a novel biomarker for patients with NSCLC 17 19 . However, the literature revealed that the characterization of DLEC1 methylation in the diagnosis of patients with lung cancer was still debatable. Studies with a small number of samples might produce spurious results.
To present the correct conclusion by ruling out the wrong results, a meta-analysis was conducted to help establish the diagnostic performance of DLEC1 methylation in lung cancer.
Methods and Materials

Identification of Eligible Studies for the Current
Meta-analysis
A literature search was conducted using the combined keywords among the online literature libraries including We used the following criteria to select eligible studies from the literature: 1) all the studies were case-control based studies of DLEC1 methylation; 2) all the cancer tissues in the cases were diagnosed by experienced physicians; 3) control tissues must have been non-cancerous ones from benign lung disease or healthy persons or the adjacent non-cancerous tissues of patients with lung cancer; 4) the studies must have contained sufficient information to infer DLEC1 methylation frequency.
Extraction of DLEC1
Among the retrieved full-text articles, we extracted the first author's name, published year, ethnicity, types of samples, detection method of methylation, the number of patients with lung cancer, the number of non-cancerous lung samples, and the number of methylations.
Statistical Analysis
All the statistical analyses were performed using Re- . We defined a significant heterogeneity in the meta-analysis if it had a P < 0.05 in the Q statistical test or I 2 > 50%, and we applied a random-effect model for the meta-analysis with significant heterogeneity, otherwise a fixed-effect model was applied 20 . The diagnostic value of DLEC1 methylation in the risk of lung cancer was evaluated using the pooled sensitivity and specificity, positivelikelihood ratio (PLR), negative-likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) in the summary receiver operating characteristics (SROC) test.
Results
Study Characteristics
As shown in Figure 1 , our initial literature search identified a total of 71 articles from the online databases including PubMed, Enbase, CNKI, and Wanfang. Among the articles, we excluded 24 overlapping articles among the various databases. A further check filtered out 31 irrelevant articles and 9 articles without sufficient data. At last, we identified 7 eligible articles (8 case-control studies) for the current meta-analysis.
Meta-analysis of DLEC1
DLEC1 methylation was assessed among a total of 673 cases of lung cancer and 581 control samples from 8 studies. Further analysis indicated no heterogeneity in the current meta-analysis (I 2 = 0%). Therefore, a fixed- effect model was applied for the current meta-analysis.
Our results showed a significant association of DLEC1 hypermethylation with lung cancer (P < 0.00001, OR = 13.93, 95% CI = 9.44-20.55, Fig. 2A ). The funnel plots were largely symmetrical, suggesting that there was no publication bias in the current meta-analysis (Fig. 2B) .
Subgroup Meta-analysis in CRC Samples
Among the 8 studies, DLEC1 methylation was detected by an MSP method in Asian patients with lung cancer Table 1 . Moreover, DLEC1 methylation was detected in CRC tissues (n = 4) and plasma (n = 4), therefore, we performed a subgroup meta-analysis by sample type. 
cer and the lymph node status, and the pooled data indi- methylation in the prediction of lung cancer risk (Fig. 6 ).
This suggests a potential usage of DLEC1 methylation in the diagnosis of lung cancer.
Discussion
The poor outcome of patients with lung cancer is partly because more than one-half of cases are diagnosed at a late stage 3 . Currently, the best way to solve this problem is earlier diagnosis with successful surgical intervention 21 .
Thus, developing new ways for early diagnosis may help to improve the quality of life of patients with lung cancer. Nowadays, a number of potential biomarkers have been reported, but very few have reached clinical standards to be an efficient index due to small study sizes and lack of assay optimization 22, 23 . The aberrant of DLEC1 methylation had been reported in several cancers, such 
as prostate cancer 24 , gastric cancer 25 , and lung cancer 18 .
However, the diagnostic role of the methylation status of the DLEC1 gene in lung cancer lacks comprehensive assessment. We therefore performed a meta-analysis to evaluate the diagnostic ability for the DLEC1 methylation in lung cancer.
In the meta-analysis, the results revealed that DLEC1 Previous studies demonstrated that the rate of WIF1 27 and CHFR 28 hypermethylation was higher in SCC than in AC. Our subgroup analysis revealed that the frequency of DLEC1 methylation was also significantly higher in SCC than AC, suggesting the usefulness of DLEC1 methylation as a biomarker in differentiating SCC and AC.
And the molecular mechanism may be different between SCC and AC. However, the definitive mechanism should be confirmed in future studies.
It was reported that there was a novel mechanistic link between aberrant hypermethylation in cancer and aging 29, 30 . In the current study, DLEC1 hypermethylation was found in the older population (age ! 60 years old), which provided a potentially age-specific biomarker of lung cancer. Unfortunately, only 3 studies were included in this subgroup meta-analysis. More studies are needed to broadly establish this association in lung cancer.
DLEC1 was more frequently methylated in patients with lung cancer with lymphatic metastasis than those These results demonstrated that DLEC1 methylation may play an important role in the occurrence and development of lung cancer.
There were several limitations in this meta-analysis.
Firstly, all the eligible studies were performed in Asian patients. There were only a few studies from Caucasians and Africans. Therefore, more studies with a larger number of participants are needed to assess the association in Caucasians and Africans. Secondly, the methylation evaluation of DLEC1 was based on one region, which might not be representative of the whole gene. Moreover, the great diversity of the primers used in each individual article might be one of the explanations for the discrepancy of DLEC1 methylation in the detection of lung cancer risk.
In conclusion, this study indicated that DLEC1 methylation might be a valuable diagnostic biomarker for lung cancer.
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